Silymarin [Milk Thistle Extract] in the treatment of chronic liver diseases: Past and future – Source: Orvosi Hetilap, Dec 2008, article in Hungarian
by Janos Feher, Gabriella Lengyel
April 17, 2009
[Note: Though the article is in Hungarian, the extensive list of journal references cited in this review is available in English at the journal site.]
In the treatment of chronic liver diseases adequate therapy can be chosen only in the knowledge of pathogenetic processes.
In the liver diseases caused by oxidative stress (alcoholic and non-alcoholic fatty liver and steatohepatitis, drug- and compound-induced liver toxicity) the antioxidant drugs, like silymarin, in chronic hepatitis caused by hepatitis B and hepatitis C virus, combined peginterferon and nucleosid treatments are the primary therapy modalities to be selected.
The main effects of silymarin are the membrane stabilizing and antioxidant effects:
• It is able to help the liver cell regeneration,
• It can decrease the inflammatory reaction and inhibit the fibrogenesis in the liver.
These results have been established by experimental and clinical trials.
• According to open studies, the long administration of silymarin significantly increased the survival time of patients with alcohol-induced liver cirrhosis.
• Recently it was demonstrated that high-dosage silibinin infusion treatment could significantly decrease the number of hepatitis C viruses after four-week application.
• On the basis of the results with the methods of molecular biology, silymarin is able to decrease significantly tumor cell proliferation, angiogenesis as well as insulin resistance.
These results support the administration of silymarin preparations in the therapy of chronic liver diseases, especially in alcoholic and non-alcoholic steatohepatitis in current clinical practice, and as it can be awaited, also in the future.
In some neoplastic diseases [involving abnormal tissue growth] they could also be administered as adjuvant therapy.
Source: Orvosi Hetilap [Published in Hungary], Dec 2008; 149(51) pp 2413-2418. PMID: 19073452, by Feher J, Lengyel G. Semmelweis Egyetem, Altalanos Orvostudomanyi Kar II. Belgyogyaszati Klinika Budapest Szentkiralyi, Hungary. [E-mail: feher@bel2.sote.hu]
http://www.astenzymes.com
The products and the claims made about specific products on or through this site have not been evaluated by the United States Food and Drug Administration and are not intended to diagnose, treat, cure or prevent disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. Please view our full Terms Of Use Agreement for more information and the terms and conditions governing your use of this site.
